Arvinas, Inc. (NASDAQ:ARVN) Forecasted to Post Q1 2025 Earnings of ($1.14) Per Share

Arvinas, Inc. (NASDAQ:ARVN) – Investment analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Arvinas in a research note issued on Tuesday, July 30th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($1.14) for the quarter. Wedbush has a “Outperform” rating and a $57.00 price target on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($4.08) per share. Wedbush also issued estimates for Arvinas’ Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($0.93) EPS and Q4 2025 earnings at ($0.68) EPS.

A number of other research firms have also weighed in on ARVN. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $87.00 target price on shares of Arvinas in a research note on Thursday. Oppenheimer reduced their target price on Arvinas from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Wednesday. Barclays reduced their target price on Arvinas from $60.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Wells Fargo & Company reduced their target price on Arvinas from $63.00 to $60.00 and set an “overweight” rating on the stock in a research note on Thursday, May 9th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $58.33.

Arvinas Stock Down 3.5 %

Shares of ARVN opened at $25.84 on Thursday. The business has a fifty day moving average of $27.92 and a 200 day moving average of $35.91. Arvinas has a 52-week low of $13.57 and a 52-week high of $53.08. The company has a market cap of $1.77 billion, a PE ratio of -4.36 and a beta of 1.98.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.59. The company had revenue of $76.50 million during the quarter, compared to the consensus estimate of $33.27 million. The firm’s quarterly revenue was up 40.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.25) earnings per share.

Hedge Funds Weigh In On Arvinas

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Arvinas by 2.0% in the third quarter. Vanguard Group Inc. now owns 4,608,223 shares of the company’s stock worth $90,505,000 after acquiring an additional 90,426 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Arvinas by 363.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,370 shares of the company’s stock worth $262,000 after purchasing an additional 4,996 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Arvinas during the fourth quarter worth about $2,202,000. DekaBank Deutsche Girozentrale lifted its holdings in Arvinas by 110.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 42,000 shares of the company’s stock valued at $1,764,000 after acquiring an additional 22,000 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Arvinas by 39.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 11,510 shares of the company’s stock valued at $474,000 after acquiring an additional 3,274 shares during the period. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.